In an elegant study, Kleinbongard et al. [7] developed a strategy for the quantification of protein expression and phosphorylation in multiple tissue samples taken from various experiments on different gels/membranes by Western blot. Here, they analyze "survival signaling" proteins and their phosphorylation in left ventricular biopsies taken from the previous pig studies on ischemic preconditioning (IPC), ischemic postconditioning (POCO), and remote ischemic conditioning (RIPC). They show that neither the expression nor the phosphorylation of the classical protective signaling proteins (AKT, ERK1/2, GSK-3beta, p38 MAPK, or PKG) were associated with reduced infarct size by different conditioning strategies, and that only STAT3 phosphorylation (when normalized to total STAT3 expression) was consistently associated with cardioprotection obtained by ischemic preconditioning but not by the other conditioning strategies. In the light of the lack of successful translation of many preclinical cardioprotection data to clinical therapy, these results might not be surprising [4] . However, given the abundance of preclinical papers (including studies in pigs) claiming that above survival protein kinases are important mediators of ischemic conditioning, one may question the reproducibility of individual preclinical studies/data and ask a more important question, how to move forward in finding valid molecular targets for cardioprotection (see for a recent position paper [3] ).
What do we learn from the above study by Kleinbongard et al. [7] ?
1. It is, indeed, important to validate the published experimental animal data by meta-analyses (as done routinely with clinical data) to assess/validate the robustness of an analyzed signaling cascade. Such a meta-analysis could include repetitive data from a single laboratory (as presented by Kleinbongard et al. [7] ) or-even better-from different laboratories publishing on the same signaling cascade. For the latter, however, standardized experimental protocols are a pre-requisite. Rigorous quality control of studies across laboratories is challenging; therefore, a recent global European action is aiming for it (http://www.cost.eu/COST_Actions/ca/CA16225). 2. It is also important to decide on the best method to assess changes in the efficacy/activity of a signaling cascade under pathophysiological conditions. Direct measurement of protein activity is often substituted by assessment of its posttranslational modifications (e.g., phosphorylation in absolute terms or normalized to protein expression) or relative expression, the latter might be the weakest indicator for protein activity. The unknown time course of protein activation/inactivation and the possibility to assess only a few time points are further limitations in in vivo experimental studies. As in the study of Kleinbongard et al. [7] , pigs might be best suited for such analysis as compared to other species, since repetitive tissue sampling is possible; however, here, the contribution of irreversibly injured and viable tissue to the overall signal is not possible to be quantified in small tissue biopsies. Finally, species dependence of signaling cascades is always a matter of concern (e. , and the importance of certain proteins for cardioprotection has finally to be proven in humans [6] . 3. Problems of reproducibility of data may also be due to biased selection of targets based on a hypothesis that may lead to lack of proper randomization and biased interpretation of the data. Therefore, target findings may also be done using unbiased "fishing" approaches, such as "multi-omics" assays including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, followed by dynamic network analysis to predict the most relevant targets [9] . In acute cardioprotection, epigenomic alterations may be relevant, but so far, there is no study in this field. Technical limitations in full proteomics from heart tissue (see, e.g., [2] ) and metabolomics show that these technologies may not be ready for fishing approaches. Therefore, currently, transcriptomics seems to be useful for unbiased target identification at the transcript level (see for reviews [9, 10] and a recent original paper in pigs [8] ). Maybe, an easier way of unbiased omics approach is to detect miRNA fingerprints (miRNAs are of limited number and they regulate gene expression) of non-ischemic and ischemia/reperfused hearts with and without conditioning, and identify cardioprotective miRNAs termed "protectomiRs" by a systematic comparison of miRNA expression changes between groups as described [11] . Based on the identified protectomiRs, prediction of their common mRNA targets by bioinformatics methods based on topological or network dynamical approaches can be done (currently, user friendly software is under development, e.g., mirnatarget.com). Nevertheless, all unbiased omics approaches and their bioinformatic evaluation need to be followed by rigorous experimental validation of the predicted targets at the transcript and protein levels (Fig. 1 ).
In conclusion: Kleinbongard et al. [7] highlight the importance of validation of individual experimental data by subsequent meta-analyses as done routinely in the clinical setting also for preclinical studies. However, their results also demonstrate that many questions regarding proper target selection (biased vs. unbiased approaches and species dependence) and analysis (protein expression, modification, and activity) need to be solved to facilitate a better translation of experimental findings into daily clinical routine. 
